AusperBio raises $50 million in Series B+ funding to advance a functional cure for chronic hepatitis B, led by an existing industry-leading investor.
Amount Raised
$50 Million
Round Type
Series B
Investors
Description
AusperBio has completed a $50 million Series B+ financing round to support its clinical development of AHB-137 for chronic hepatitis B. This round was oversubscribed and saw participation from several prominent investors. The funding will facilitate Phase II trials and commercial manufacturing partnerships. The successful financing underscores strong investor confidence in AusperBio's strategic direction.
Quick answer
AusperBio raised $50 Million in a Series B round, dated May 28, 2025. Investors: Hankang Capital, Yuanbio Venture Capital, Sherpa Capital, Genesis Capital, CDH Investments and Qiming Venture Partners.
- How much did AusperBio raise?
- AusperBio raised $50 Million in a Series B round on May 28, 2025.
- Who invested in AusperBio?
- Hankang Capital, Yuanbio Venture Capital, Sherpa Capital, Genesis Capital, CDH Investments and Qiming Venture Partners are named as investors in this round.
- What does AusperBio do?
- AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to advancing oligonucleotide and targeted delivery technologies for transformative therapies, with an initial focus..
- Where is AusperBio based and how big is it?
- Fundz records about 100 employees.
- Who are the decision-makers at AusperBio?
- Fundz holds 4 contacts at AusperBio, including the Co-Founder & CEO. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biopharma around the same time
Companies in the same sectors as AusperBio that raised within 45 days of this round, from Fundz verified event records.
- Os Therapies raised $4.2M on June 23, 2025.
- Ensho Therapeutics raised $23M on June 12, 2025.
- Mezzion Pharma raised $20M (Funding Round) on June 11, 2025.
- Retension Pharmaceuticals raised $12M on April 22, 2025.
- Renasant Bio raised $55M (Seed) on July 10, 2025.
- Nuclidium raised $98M (Series B) on July 10, 2025.
Who to call at AusperBio, and when
A new round usually means AusperBio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day AusperBio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at AusperBio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at AusperBio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment AusperBio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAusperBio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.